Drug manufacturers GlaxoSmithKline, its employees bribing doctor on Thursday said its chief financial officer has been banned from leaving the country.
Executive, Steve Nechelput, without being questioned or arrested and travel freely within China, the British company said in a statement. It says it has been known to travel restrictions because of the end of June. Nechelput continue to serve as chief financial officer for the company's China unit of work.
Chinese police announced this week that they have detained four suspected of doctors, hospitals and other pharmaceutical companies to encourage them to open GlaxoSmithKline employees.
Police said as many as 300 million yuan funnel employees ($ 490 million) bribe hidden source through travel agencies and consulting firms, according to Chinese news reports. The survey also no clear how much money to pay bribes.
The official Xinhua News Agency said the program aims to evade GlaxoSmithKline's internal controls to prevent bribery.
GlaxoSmithKline has said it opposes bribery, and to cooperate with the investigation.
On Wednesday, Chinese drug regulatory departments in its pharmaceutical market misconduct launched a blow, but it gave no indication that it has with GlaxoSmithKline probes.
State Food and Drug Administration, said the event aims to eradicate illegal drug production, improper drug retail and online sales of counterfeit Chinese traditional medicine.
In November came the new Chinese leadership has pledged to improve China's health system and the control of medicines and medical costs rise, fueling public frustration.
China has suffered a scandal, some of which counterfeit drugs causing death and injury. False advertising and other violations, regulators have launched a number of strikes, but with limited success.
Also on Wednesday, the Ministry of Commerce spokesman warned that Chinese and foreign pharmaceutical manufacturers will face "legal sanctions" misconduct.
Meanwhile, the Cabinet's planning agency is investigating 60 Chinese and foreign pharmaceutical manufacturers production costs, according to state media, it may be a prelude to a key drug price cap revision of the national provisions.
 



Other News:
China bars Glaxo finance chief from leaving
Kurd militants make ＂final warning＂ to Turkey on peace process
Eli Lilly to freeze employee base pay ahead of generic onslaught
Shareholders voting on $24.4 billion Dell buyout
A look at the next steps for Detroit
China hikes tariff on US, Korean solar polysilicon
Exclusive: GM delays Chevy Cruze debut by a year
Asiana no longer suing San Francisco TV station